top of page

ONCOLOGY BUSINESS REVIEW

The Rise — and fall? — of Avastin

A look at the FDA's controversial review of Avastin's indication for advanced metastatic breast cancer.

Download PDF

Taking it Personal: When to Add Biomarkers to Treatment Guidelines

The role of diagnostics in the future of cancer drug development is central to the personalization of therapy. But numerous issues surround the incorporation of biomarkers into treatment guidelines.

Download PDF

Targeting Therapy: New Approaches to Finding the Next Great Cancer Drug

The next big breakthrough depends not only on the lab bench but also—and perhaps more so—on the willingness of all those involved to work cooperatively and take greater risks.

Download PDF

The Future of the Present: A look at current and proposed state legislation to regulate and disclose gifts

New state laws to restrict and monitor the giving of gifts from pharma reps to doctors are popping up across the country.

Download PDF

Behind Closed Network Doors: Oral cancer drugs and the rise of specialty pharmacy

New state laws to restrict and monitor the giving of gifts from pharma reps to doctors are popping up across the country.

Download PDF

bottom of page